NCT03748628

Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-305 Following a Single Oral Dose in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Enanta Pharmaceuticals, Inc · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-305 in healthy male subjects.

Conditions

• NASH - Nonalcoholic Steatohepatitis

Interventions

Type	Name	Description
DRUG	EDP-305	\[14C\]EDP-305

Timeline

• Start date: 2018-10-05
• Primary completion: 2018-10-13
• Completion: 2018-10-13
• First posted: 2018-11-21
• Last updated: 2018-11-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study